The Pneumocell-study: Vaccination of IgG1- and IgG2-deficient patients with Prevnar13
The Pneumocell-study: Vaccination of IgG1- and IgG2-deficient patients with Prevnar13
About this item
Full title
Author / Creator
Publisher
Netherlands: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Netherlands: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Highlights • IgG-deficient patients responded to Prevnar13 vaccination with lower Opa-titers than controls. • An almost normal vaccine response to pneumococcal serotypes 6A and 6B was recorded. • Most IgG-deficient patients reached Opa-titers of ≥8 and anti-pneumococcal IgG levels of 0.35 µg/ml by 4 weeks post vaccination. • Prevnar13 could confer...
Alternative Titles
Full title
The Pneumocell-study: Vaccination of IgG1- and IgG2-deficient patients with Prevnar13
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_swepub_ki_se_497537
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_497537
Other Identifiers
ISSN
0264-410X
E-ISSN
1873-2518
DOI
10.1016/j.vaccine.2017.03.097
